Bayer to acquire full ownership of radium-223

According to a report on the MarketWatch web site this morning, Bayer AG’s acquisition of Algeta will be completed before the end of March this year, at which time Bayer will become the sole owner of radium-223 (Xofigo) with full responsibility for the future development and marketing of this drug currently indicated for the treatment of late stage prostate cancer.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: